This latest investment, combined with newly awarded Stage 3 funding from the Japan Agency for Medical Research and Development (AMED), brings the biotech startup’s cumulative funding to approximately JPY 3.42 billion. The company intends to direct these resources toward manufacturing, safety assessments, and regulatory filings required for its upcoming Investigational New Drug (IND) application in the United States.
In section Releases
Celaid Therapeutics Secures JPY 400 Million to Advance Stem Cell Therapy
Tokyo-based Celaid Therapeutics has closed the second stage of its Series B financing, bringing in JPY 400 million from new investors Shionogi & Co. and Teikoku Ventures. The capital injection accelerates the company’s push toward U.S. clinical trials for its lead candidate, CLD-001, a novel hematopoietic stem cell therapy.
CLD-001 targets severe pediatric non-malignant diseases by utilizing proprietary technology to expand hematopoietic stem cells harvested from umbilical cord blood. By overcoming the traditional limitations of cell volume and donor matching, the therapy aims to improve survival outcomes for patients requiring transplants. With a Pre-IND meeting already completed with the FDA and technology transfer finalized with a U.S. contract manufacturer, Celaid is now prioritizing the transition to first-in-human clinical trials.
Comments (0)
No comments yet. Be the first!